tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

BCAX Stock Latest News

Positive Outlook for Bicara Therapeutics: Promising Phase 1b Results and Safety Profile Support Buy Rating
RatingsPositive Outlook for Bicara Therapeutics: Promising Phase 1b Results and Safety Profile Support Buy Rating
5d ago
BCAX
Buy Rating for Bicara Therapeutics Driven by Promising Efficacy and Safety of FICERA in ESMO Asia Abstract
PremiumRatings
Buy Rating for Bicara Therapeutics Driven by Promising Efficacy and Safety of FICERA in ESMO Asia Abstract
7d ago
BCAX
Bicara Therapeutics Inc. (BCAX) Q3 Earnings Cheat Sheet
PremiumPre-Earnings
Bicara Therapeutics Inc. (BCAX) Q3 Earnings Cheat Sheet
21d ago
BCAX
Promising Drug Pipeline and Upcoming Trial Data Support Buy Rating for Bicara Therapeutics
PremiumRatings
Promising Drug Pipeline and Upcoming Trial Data Support Buy Rating for Bicara Therapeutics
27d ago
BCAX
Bicara Therapeutics reports Q3 EPS (67c), consensus (53c)
PremiumThe Fly
Bicara Therapeutics reports Q3 EPS (67c), consensus (53c)
27d ago
BCAX
Bicara Therapeutics’ FORTIFI-HN01 Study: A Promising Step in Cancer Treatment
PremiumCompany AnnouncementsBicara Therapeutics’ FORTIFI-HN01 Study: A Promising Step in Cancer Treatment
1M ago
BCAX
Bicara Therapeutics’ Innovative Approach to EGFR-Driven Tumors: A Clinical Study Update
Premium
Company Announcements
Bicara Therapeutics’ Innovative Approach to EGFR-Driven Tumors: A Clinical Study Update
1M ago
BCAX
Bicara Therapeutics: Strategic Advantages and Favorable Safety Profile Drive Buy Rating
Premium
Ratings
Bicara Therapeutics: Strategic Advantages and Favorable Safety Profile Drive Buy Rating
2M ago
BCAX
Bicara sinks after J&J reports head and neck cancer data
PremiumThe Fly
Bicara sinks after J&J reports head and neck cancer data
2M ago
JNJ
BCAX
Bicara Therapeutics management to meet with Cantor Fitzgerald
PremiumThe Fly
Bicara Therapeutics management to meet with Cantor Fitzgerald
2M ago
BCAX
Bicara Therapeutics announces ficerafusp alfa granted BTD by U.S. FDA
PremiumThe Fly
Bicara Therapeutics announces ficerafusp alfa granted BTD by U.S. FDA
2M ago
BCAX
Bicara Therapeutics files $400M mixed securities shelf
PremiumThe Fly
Bicara Therapeutics files $400M mixed securities shelf
2M ago
BCAX
Promising Market Opportunity for Bicara Therapeutics in HPV-Negative Head & Neck Cancer Warrants Buy Rating
PremiumRatingsPromising Market Opportunity for Bicara Therapeutics in HPV-Negative Head & Neck Cancer Warrants Buy Rating
2M ago
BCAX
Optimistic Buy Rating for Bicara Therapeutics: Superior Clinical Benefits and Valuation Upside
Premium
Ratings
Optimistic Buy Rating for Bicara Therapeutics: Superior Clinical Benefits and Valuation Upside
2M ago
BCAX
Bicara Therapeutics initiated with a Buy at JonesResearch
Premium
The Fly
Bicara Therapeutics initiated with a Buy at JonesResearch
3M ago
BCAX
Bicara Therapeutics price target lowered to $40 from $41 at H.C. Wainwright
PremiumThe Fly
Bicara Therapeutics price target lowered to $40 from $41 at H.C. Wainwright
4M ago
BCAX
Bicara Therapeutics initiated with an Overweight at Piper Sandler
PremiumThe Fly
Bicara Therapeutics initiated with an Overweight at Piper Sandler
4M ago
BCAX
Bicara Therapeutics initiated with an Overweight at Piper Sandler
PremiumThe Fly
Bicara Therapeutics initiated with an Overweight at Piper Sandler
4M ago
BCAX
Bicara Therapeutics Reports Q2 2025 Results and Progress
PremiumCompany Announcements
Bicara Therapeutics Reports Q2 2025 Results and Progress
4M ago
BCAX
Promising Clinical Developments and Financial Stability Drive Buy Rating for Bicara Therapeutics
PremiumRatingsPromising Clinical Developments and Financial Stability Drive Buy Rating for Bicara Therapeutics
4M ago
BCAX
Bicara Therapeutics reports Q2 EPS (50c), consensus (54c)
Premium
The Fly
Bicara Therapeutics reports Q2 EPS (50c), consensus (54c)
4M ago
BCAX
Bicara Therapeutics expects cash to fund operations into 1H of 2029
Premium
The Fly
Bicara Therapeutics expects cash to fund operations into 1H of 2029
4M ago
BCAX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >